CYCLERION THERAPEUTICS, INC.

CYCN

CIK 0001755237 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$1M
↓-43.2% -$781Kvs FY2024 (Q4)
Operating Income
$506K
↓-71.1% -$1Mvs FY2024 (Q4)
Net Income
$506K
↓-4.5% -$24Kvs FY2024 (Q4)
Gross Profit
$1M
↓-43.2% -$781Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
17/100
  • Profitability
    0ROIC -43.8% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 5.15 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    1Asset Turnover 0.21x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -43.2% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -115.0% · trend -655.8pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
investment in PP&E
Stock-based comp (TTM)
$441K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$10M
everything owned
Stockholders' equity
$9M
shareholder claim

Recent performance · 32 quarters

Revenue↓-43.2% -$781K
$1M
Net Income↓-35.0% -$253K
$-976K
Free Cash Flow↑+48.3% +$903K
$-968K
Operating Margin↑+466.5pts
-115.0%

Drill down